Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.
Phase 2
- Conditions
- unrecectable or recurrent advanced gastric cancer
- Registration Number
- JPRN-UMIN000015431
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Anticancer Res. 2018 Dec;38(12):6911-6917. doi: 10.21873/anticanres.13068.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
1.With history of receiving paclitaxel treatment 2.With serious drug allergy 3.With servaral comorbid disease poorly controlled diabetes poorly controlled hypertension liver cirrhosis, liver failure renal failure intestitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema active infectious disease heart failure, myocardial infarction, angina pectoris or ECG abnormalities within 6 months 4.With active anothor cancer 5.With peripheral neuropathy greater than grade2 6.With HBs antigen positive 7.With pregnant or nursing women 8.Cases who physician judged improper to entry this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival(OS),Progression free survival(PFS),Safty, Time to progression(TTP)